Flatiron Health

At Flatiron Health, we’re filling critical evidence generation gaps with oncology #RWD from the UK, Germany, and Japan and gaining insights from patients with various cancers through global studies that were previously impossible. Access to global real-world data allows us to conduct comparative effectiveness research, improving the precision and effectiveness of targeted therapies and much, much more. Learn more from Head of Outcomes Research & Evidence Generation, Blythe Adamson, PhD, MPH ⬇️

“The amount of evidence we need to generate as an industry is way out of alignment with what we can actually supply." Despite this imbalance, all hope is not lost. There is a critical role that technology can play in evidence generation. Flatiron’s Director of Clinical Operations, Josh Buddle, discusses the use of technology as part of prospective #evidencegeneration in this interview with Research Revolution: http://spkl.io/6041f6ypD

ANNOUNCED TODAY: Flatiron Health will be attending the 2024 International Association for the Study of Lung Cancer World Conference on Lung Cancer, showcasing how our evidence solutions can be leveraged to bolster lung cancer research across the product development lifecycle. Learn more about how Flatiron is unlocking critical insights in lung cancer research with panoramic data with maximum cohort sizes of over 290K lung cancer patients. #WCLC24 https://lnkd.in/eXahWcYv

Can we re-evaluate the approach to data acquisition for #clinicaltrials for the sake of timelines and our teams? Hear from our Director of Clinical Operations, Josh Buddle, as he reflects on a topic we evaluate frequently as part of prospective evidence generation: the role of data in post-marketing trials. Watch the full episode with Research Revolution here: http://spkl.io/6041f6yT1

The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.

Spearheaded by Friends of Cancer Research, a research collaboration between #RWD providers, pharmaceutical companies, academics, researchers, and experts from government agencies was recently published in JCO Clinical Cancer Informatics ⤵️ #RWEFriends As use of #RWD to support drug development and regulatory decision-making continues to be prioritized, aligning on methodologies for aggregating and analyzing this data is critical to ensure it is a reliable and consistent source of information. Using data from 7 RWD partners, including Flatiron Health, the researchers found RWD has the ability to increase understanding of therapies effectiveness, including when specific populations are underrepresented in clinical trials or to identify populations for future trials or label expansions on already approved therapies. For more on this research and why is matters, visit our website: http://spkl.io/6043f6ZHS

Flatiron Health will be leading discussions on key innovations and the future of oncology care at the upcoming Clinical Pathways Congress + Cancer Care Business Exchange Experts James Hamrick, Will Shapiro, Rebecca Maniago, PharmD, BCOP, and Nina Chavez will be participating in 3 key panels: - Digital Innovation: Cancer-Specific #AI Use Cases - How to Build Your Own Pathway Program - Strategies for Patient Navigation Services To connect directly with our team onsite, visit us at booth #17 or schedule a meeting today: https://lnkd.in/egnYrU-g #CPC_CBEx

Our collaboration with Canopy not only supports our provider network, but has the potential to improve patient care and outcomes. Read the below article, published in AJMC - The American Journal of Managed Care, for an in depth review of how continuous care management is driving progress towards our mission to improve and extend lives by learning from the experience of every person with cancer.

Flatiron Health’s South Asian Employee Resource Group (ERG), Desi, gathered together over the last month to recognize #SouthAsianHeritageMonth (SAHM). Throughout the month, the group gathered to share traditions, reflect on important historical events, and explore the diaspora and diversity of cultural identities across the region. This year, Desi celebrated #SAHM in numerous ways including a tour of the Rubin Museum of Art in New York City, a space dedicated to celebrating the art and cultures of the Himalayas and surrounding regions, and they plan to wrap up their celebrations with a Desi Media Club event where they will discuss the book “The Twentieth Wife” by Indian-American author, Indu Sundaresan.

#AI continues to reshape and reinvent many aspects of #cancercare. Flatiron Health's Head of Clinical Oncology & Patient Safety and Vice Chair of Electronic Health Record Association’s AI Task Force Stephen Speicher, M.D., M.S., is using his combined product knowledge and clinical expertise to inform AI’s impact on regulatory frameworks in #HealthcareIT. Read more on how the the EHR Association’s AI Task Force is providing thought leadership, guidance, and advocacy, to ensure safe use of #AI in #healthcare: https://lnkd.in/gJi58WMZ